METHODS: An observational, retrospective, multicenter study that included patients ≥ 18 years old who had histologically documented mCRC and who had initiated treatment with regorafenib since January 2017. Post hoc categorization of dosing patterns revealed the following: initial dose < 160 mg and dose escalation, initial dose < 160 mg and maintenance, initial dose equal to 160 mg and maintenance, and initial dose equal to 160 mg and dose reduction.
RESULTS: Most patients (152/241, 63.8%) initiated treatment with regorafenib at doses < 160 mg. There was large variation in the starting dose of regorafenib over time: in 2017, most patients (59%) initiated regorafenib at a dose of 160 mg, this proportion decreased to 6% in 2021. There were no significant differences in the median progression-free survival according to the regorafenib dose patterns during the first two cycles. The proportion of patients who reported at least one adverse event (AE), had a grade 3-4 AE or had an AE leading to dose reduction was greater in the group of patients who received an initial dose equal to 160 and reduction.
CONCLUSIONS: Our results indicate that physicians in Spain have gradually adopted a dose-escalation approach during cycle 1, which is a common practice for starting treatment with a reduced dose (< 160 mg/day), a strategy that seems to improve tolerability while maintaining efficacy.
BACKGROUND: Not applicable.
方法:观察性,回顾性,多中心研究纳入组织学记录为mCRC且自2017年1月开始使用瑞戈非尼治疗的≥18岁患者.给药模式的事后分类显示:初始剂量<160mg和剂量递增,初始剂量<160毫克和维持,初始剂量等于160毫克和维持,和初始剂量等于160毫克和剂量减少。
结果:大多数患者(152/241,63.8%)开始接受剂量<160mg的瑞戈非尼治疗。随着时间的推移,瑞戈非尼的起始剂量有很大变化:2017年,大多数患者(59%)以160mg的剂量开始瑞戈非尼,这一比例在2021年下降到6%。根据前两个周期的regorafenib剂量模式,中位无进展生存期没有显着差异。报告至少一次不良事件(AE)的患者比例,在接受初始剂量等于160并减少剂量的患者组中,出现3-4级AE或导致剂量减少的AE更大.
结论:我们的结果表明,西班牙的医生在第1周期中逐渐采用了剂量递增方法,这是以减少剂量(<160mg/天)开始治疗的常见做法,一个策略,似乎提高耐受性,同时保持疗效。
背景:不适用。